UPDATE : Tuesday, November 12, 2019
상단여백
[News Focus] ‘FDA could allow resumption of Invossa trial’ by Jeong Sae-im 2019-11-12 15:48
Celltrion marks robust Q3 sales by Lee Han-soo 2019-11-07 14:03
Samsung Bioepis, Biogen to commercialize next-generation biosimilar candidates by Lee Han-soo 2019-11-07 11:16
Court rejects arrest warrant for 2 Kolon execs by Jeong Sae-im 2019-11-05 13:54
Samsung BioLogics to make Ichnos Sciences’ atopic dermatitis treatment by Lee Han-soo 2019-11-05 12:47
라인
Prosecutors seek to arrest 2 Kolon execs for false Invossa data by Jeong Sae-im 2019-10-31 15:34
Syntekabio passes prior review for Kosdaq listing by Jeong Sae-im 2019-10-31 13:27
Prosecution seeks jail term for Samsung execs for destroying evidence by Jeong Sae-im 2019-10-29 13:10
KangStem Biotech changes strategy for atopic dermatitis drug by Jeong Sae-im 2019-10-28 15:34
Bridge Biotherapeutics passes preliminary review for Kosdaq listing by Jeong Sae-im 2019-10-25 15:05
라인
Celltrion launches Herzuma in Brazil by Lee Han-soo 2019-10-25 13:56
KangStem Biotech fails in phase-3 study on atopic dermatitis drug by Jeong Sae-im 2019-10-25 11:17
Samsung Bioepis' biosimilar sales in EU top $180 million in Q3 by Lee Han-soo 2019-10-23 17:43
Medipost wins patent for mesenchymal stem cell culture in China by Lee Han-soo 2019-10-23 16:30
Celltrion unveils clinical results of Remsima SC in treating IBD by Lee Han-soo 2019-10-22 17:00
라인
Biogen, Samsung Bioepis to present biosimilar data at EU conference by Lee Han-soo 2019-10-22 11:31
Medytox exported ₩3.3 billion worth of unqualified BTX by Jeong Sae-im 2019-10-18 16:02
State organs squandered ₩8.2 billion; failed to spot Invossa problem by Kwak Sung-sun 2019-10-16 15:06
[Exclusive] Samsung admits it failed to develop Rituxan biosimilar by Jeong Sae-im 2019-10-16 14:16
Kolon Life Science shares surge after TissueGene’s survival by Jeong Sae-im 2019-10-14 18:01
여백
여백
여백
Back to Top